A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol

INTRODUCTION: There are currently no effective treatments preventing conversion from mild cognitive impairment (MCI) to Alzheimer's disease. Cilostazol is a selective type-3 phosphodiesterase inhibitor that ameliorates accumulation of amyloid-β and has prevented cognitive decline in rodent mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Satoshi, Kojima, Shinsuke, Oishi, Naoya, Kakuta, Ryosuke, Maki, Takakuni, Yasuno, Fumihiko, Nagatsuka, Kazuyuki, Yamamoto, Haruko, Fukuyama, Hidenao, Fukushima, Masanori, Ihara, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651350/
https://www.ncbi.nlm.nih.gov/pubmed/29067312
http://dx.doi.org/10.1016/j.trci.2016.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651350/
https://www.ncbi.nlm.nih.gov/pubmed/29067312
http://dx.doi.org/10.1016/j.trci.2016.10.001

Ejemplares similares